Followers | 16 |
Posts | 1145 |
Boards Moderated | 0 |
Alias Born | 03/12/2010 |
Tuesday, April 18, 2017 10:44:32 AM
http://www.marketwired.com/press-release/immunovaccine-announces-dosing-first-patient-investigator-sponsored-phase-1b-2-clinical-tsx-imv-2210107.htm
Recent IMV News
- IMV Accepts an Offer from its Secured Lenders for the Sale of its Intellectual Property Assets • Business Wire • 09/01/2023 08:00:00 PM
- IMV Inc. Announces Update on CCAA Proceedings and Sales and Investment Solicitation Process • Business Wire • 07/26/2023 11:05:00 AM
- IMV Receives NASDAQ Delisting Notice • Business Wire • 05/08/2023 08:30:00 PM
- Horizon Technology Finance Announces First Quarter 2023 Financial Results • PR Newswire (US) • 05/02/2023 08:15:00 PM
- IMV Initiates Restructuring Proceedings Under the CCAA to Complete the Review of its Strategic Alternatives • Business Wire • 05/01/2023 04:30:00 PM
- IMV Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency • Business Wire • 03/31/2023 08:15:00 PM
Endexx Corporation (EDXC) Leverages Global Market Trends and Legislative Reforms to Spearhead Growth in the Cannabis and Plant-Based Wellness Sectors • EDXC • Mar 27, 2024 3:01 PM
Applied UV, Inc. Announces Pricing of $2.76 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules • AUVI • Mar 27, 2024 2:51 PM
POET and MultiLane Collaborate to Develop High-Speed Pluggable Transceivers for AI Networks • POET • Mar 27, 2024 10:52 AM
Maybacks Global Entertainment Opens 23 More Stations in Important Major Cities • AHRO • Mar 27, 2024 9:00 AM
NxGen Brands Inc. Forecast to Deliver 140% Growth in Q1 2024 • NXGB • Mar 27, 2024 7:30 AM
Kona Gold Beverages, Inc. Strategic Advancements: Covert LLC Introduces Federally Legal D9 Gummies and Revamps Innovative eCommerce Platform, Propelling Toward $12 Million Annual Revenue Goal • KGKG • Mar 26, 2024 8:30 AM